Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 6/20 | 0.56 |
| ▸ | CYP11B2 | P19099 | 6/20 | 0.56 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.47 |
| ▸ | MB | P02144 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | KDM4B | O94953 | 1/20 | 0.33 |
| ▸ | KDM5C | P41229 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6684530 | 0.85 | CYP11B1 (0.53) | CYP11B1CYP11B2PDE3BPDE3AMB | |
| SCHEMBL24982426 | 0.81 | CHRNB2 (0.47) | CYP11B1CYP11B2PDE3BPDE3ACHRNB2 | |
| SCHEMBL19553105 | 0.78 | PDE3B (0.42) | CYP11B1CYP11B2PDE3BPDE3ACHRNB2 | |
| SCHEMBL658301 | 0.74 | PDE3B (0.59) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL45104 | 0.74 | HTR5A (0.53) | CYP11B1CYP11B2PDE3BPDE3AMAPK1 | |
| SCHEMBL26463267 | 0.73 | CYP11B1 (0.62) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| SCHEMBL3462883 | 0.73 | CYP11B1 (0.56) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| Bromide SCHEMBL15650437 | 0.73 | PDE3B (0.57) | CYP11B1CYP11B2PDE3BPDE3ACYP1A2 | |
| Pyrimidine SCHEMBL29145816 | 0.73 | CYP11B1 (0.52) | CYP11B1CYP11B2PDE3BPDE3ACRBN | |
| SCHEMBL3959190 | 0.72 | PDE3B (0.40) | CYP11B1CYP11B2PDE3BPDE3ACHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122010848-A | Preparation method and detection method of key intermediate of dihydropyrido [4,3-d ] pyrimidinone analogue | 河北安健成益医药科技有限公司 | 2026-05-12 | — | — | CN | claimed |
| EP-4051677-B1 | BICYCLIC NITROGEN CONTAINING HETEROCYCLES AS INHIBITORS OF SALT-INDUCED KINASE SIK2 | CANCER RESEARCH TECH LTD (GB) | 2026-03-18 | — | — | EP | claimed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | claimed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | claimed |
| CN-122010848-A | Preparation method and detection method of key intermediate of dihydropyrido [4,3-d ] pyrimidinone analogue | 河北安健成益医药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010848-A | Preparation method and detection method of key intermediate of dihydropyrido [4,3-d ] pyrimidinone analogue | 河北安健成益医药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| CN-122010848-A | Preparation method and detection method of key intermediate of dihydropyrido [4,3-d ] pyrimidinone analogue | 河北安健成益医药科技有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4322954-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | Merck Sharp & Dohme LLC (US) | 2024-02-21 | — | — | EP | disclosed |
| EP-3708566-B1 | NOVEL HETEROCYCLIC COMPOUNDS AND THE USE THEREOF IN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2023-02-08 | — | — | EP | disclosed |
| WO-2022221739-A1 | SMALL MOLECULE INHIBITORS OF KRAS G12D MUTANT | MERCK SHARP & DOHME CORP. (US) | 2022-10-20 | — | — | WO | disclosed |
| WO-2009034029-A2 | 1-SUBSTITUTED 4-HETEROCYCLYLPIPERIDINES FOR USE AS CGRP ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-19 | — | — | WO | disclosed |
| WO-2008130615-A1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| WO-2008130615-A1 | TETRAHYDROPYRIDO[4,3-D]PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION (US) | 2008-10-30 | — | — | WO | disclosed |
| EP-1865959-A2 | PROCESS FOR PREPARING PYRIDOÝ2,3-D¨PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDOÝ4,5-D¨PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006104917-A2 | PROCESS FOR PREPARING PYRIDO[2,3-D]PYRIMIDIN-7-ONE AND 3,4-DIHYDROPYRIMIDO[4,5-D]PYRIMIDIN-2(1H)-ONE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 2006-10-05 | — | — | WO | disclosed |
| EP-1080092-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 2001-03-07 | — | — | EP | disclosed |
| WO-1999061444-A2 | BICYCLIC PYRIMIDINES AND BICYCLIC 3,4-DIHYDROPYRIMIDINES AS INHIBITORS OF CELLULAR PROLIFERATION | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0626373-A1 | Quinazolinone derivatives | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1994-11-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240217974-A1 | ISOQUINOLONE COMPOUND AND USE THEREOF | CYP4A11, CYP11B2, NQO1 | CYP11B1 5/4885CYP11B2 2/4885PDE3B 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.